LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 6, 2012--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the
completion of the sale of 1,050,000 additional shares of its common
stock pursuant to the full exercise of the over-allotment option granted
to the underwriters of its previously announced public offering. After
underwriting discounts and commissions and estimated offering expenses
payable by Synta, aggregate net proceeds from the offering were
approximately $32.9 million.
Jefferies & Company, Inc. acted as the sole book-running manager for the
offering, and Canaccord Genuity Inc. and Roth Capital Partners, LLC
acted as co-managers for the offering.
The securities described above were offered by Synta pursuant to a shelf
registration statement that was previously filed with and declared
effective by the Securities and Exchange Commission (SEC). This press
release does not constitute an offer to sell or a solicitation of an
offer to buy the securities in this offering, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction. A final prospectus supplement related to
the offering was filed with the SEC and is available on the SEC's
website located at www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Equity
Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison
Avenue, 12th Floor, New York, NY, 10022, by telephone at 877-547-6340,
or by email at Prospectus_Department@Jefferies.com.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125